Oral Mucositis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Oral Mucositis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H2 2016', provides an overview of the Oral Mucositis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
- The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects
- The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Oral Mucositis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oral Mucositis Overview 8
Therapeutics Development 9
Pipeline Products for Oral Mucositis - Overview 9
Pipeline Products for Oral Mucositis - Comparative Analysis 10
Oral Mucositis - Therapeutics under Development by Companies 11
Oral Mucositis - Therapeutics under Investigation by Universities/Institutes 12
Oral Mucositis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Oral Mucositis - Products under Development by Companies 16
Oral Mucositis - Products under Investigation by Universities/Institutes 17
Oral Mucositis - Companies Involved in Therapeutics Development 18
Aldeyra Therapeutics, Inc. 18
Cellceutix Corporation 19
Colby Pharmaceutical Company 20
Daewoong Pharmaceutical Co., Ltd. 21
Galera Therapeutics, Inc. 22
Onxeo SA 23
Oragenics, Inc. 24
Otsuka Holdings Co., Ltd. 25
Soligenix, Inc. 26
Spectrum Pharmaceuticals, Inc. 27
Spherium Biomed S.L. 28
Oral Mucositis - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
AG-013 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
brilacidin tetrahydrochloride - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
clonidine hydrochloride ER - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
dusquetide - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
GC-4419 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Gene Therapy for Oral Mucositis - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Gene Therapy for Oral Mucositis - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
KIN-219 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
nepidermin - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
NS-2 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
pralatrexate - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
rebamipide - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
SP-13004 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Oral Mucositis - Dormant Projects 75
Oral Mucositis - Discontinued Products 78
Oral Mucositis - Product Development Milestones 79
Featured News & Press Releases 79
Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis 79
Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference 79
Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis 80
May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol 81
Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide 81
Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis 82
Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis 83
Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 83
Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015 85
Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis 85
Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis 85
Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 86
Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting 87
Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 87
Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Oral Mucositis, H2 2016 9
Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016 18
Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2016 19
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2016 20
Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 21
Oral Mucositis - Pipeline by Galera Therapeutics, Inc., H2 2016 22
Oral Mucositis - Pipeline by Onxeo SA, H2 2016 23
Oral Mucositis - Pipeline by Oragenics, Inc., H2 2016 24
Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 25
Oral Mucositis - Pipeline by Soligenix, Inc., H2 2016 26
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 27
Oral Mucositis - Pipeline by Spherium Biomed S.L., H2 2016 28
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37
Oral Mucositis - Dormant Projects, H2 2016 75
Oral Mucositis - Dormant Projects (Contd..1), H2 2016 76
Oral Mucositis - Dormant Projects (Contd..2), H2 2016 77
Oral Mucositis - Discontinued Products, H2 2016 78